3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Hepatocellular
9
Neoplasms
4
Melanoma
4
Breast Neoplasms
4
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Sarcoma
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Polycystic Ovary Syndrome
2
Pleural Effusion, Malignant
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Head and Neck Neoplasms
2
Anxiety Disorders
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Recurrence
1
Rare Malignant Neoplasm
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphedema
1
Locally Advanced Bladder Cancer
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Cyclophosphamide
53
Etoposide
33
Temozolomide
28
Irinotecan
28
Melphalan
25
Filgrastim
25
Topotecan
24
Carboplatin
24
3-Iodobenzylguanidine
23
Isotretinoin
20
Granulocyte Colony-Stimulating Factor
17
sargramostim
16
humanized 3F8 anti-GD2 monoclonal antibody
16
dinutuximab
16
Granulocyte-Macrophage Colony-Stimulating Factor
16
fludarabine
15
Vincristine
15
Doxorubicin
15
Cisplatin
15
Peripheral Blood Stem Cell Transplantation
14
Interleukin-2
14
Busulfan
13
naxitamab
12
Thiotepa
12
Radiotherapy
12
aldesleukin
11
fludarabine phosphate
10
etoposide phosphate
8
Mesna
8
Ifosfamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroblastoma
×
Pharmaceutical Preparations
×
Clear all
NCT07334301
2026-01-12
BEACON2
University of Birmingham
Phase 1/2
Recruiting
160 enrolled